EMA Issues Summary of 2016 Highlights
The EMA has published a four-page document to summarize its main achievements relating to marketing authorizations of new medicines and the safety monitoring of authorized medicines during the past year.
The European Medicines Agency (EMA) has published a four-page document to summarize its main achievements relating to marketing authorizations of new medicines and the safety monitoring of authorized medicines during the past year.
The following items are referred to in the report:
- The agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 81 medicines for marketing authorization, including 27 new active substances. A total of 17 out of the 81 had an orphan designation.
- Seven medicines received a recommendation for marketing authorization following an accelerated assessment. This mechanism is reserved for medicines that have the potential to address unmet medical needs, and allows for faster assessment of eligible medicines by EMA’s scientific committees (within up to 150 days rather than up to 210 days).
- Eight medicines received a recommendation for a conditional marketing authorization, one of the possibilities in the EU to give patients early access to new medicines. This tool allows for the early approval of a medicine on the basis of less complete clinical data than normally required if the medicine addresses an urgent unmet medical need. These medicines are subject to specific post-authorization obligations for medicines developers that aim to obtain complete data on the medicine, according to EMA.
- 59 extensions of indication were recommended in 2016. The extension of the use of a medicine that is already approved in a new therapeutic indication can also offer fresh opportunities for patients, EMA stated.
To view the full document, click here.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
